PATH, in collaboration with the Directorate General Health Services (DGHS), Directorate General Drug Administration (DGDA), Government of Bangladesh (GoB) and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Bangladesh. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.